Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Csl ADR CSLLY

Healthcare Biotechnology
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures... see more

Recent & Breaking News (OTCQX:CSLLY)

Seqirus presents analysis reinforcing the safety and immunogenicity profiles of its MF59®-adjuvanted seasonal trivalent influenza vaccine in adults 65 years and older

PR Newswire August 26, 2016

Seqirus to highlight new data in seasonal influenza prevention at Options IX for the Control of Influenza conference

PR Newswire August 24, 2016

Seqirus Presents Integrated Analyses for Trivalent Adjuvanted Seasonal Influenza Vaccine for Young Children

PR Newswire Europe Non Regulatory August 24, 2016

Seqirus Presents Integrated Analyses for Trivalent Adjuvanted Seasonal Influenza Vaccine for Young Children

PR Newswire August 24, 2016

Seqirus now shipping its complete portfolio of seasonal influenza vaccines to US market for the 2016-2017 season

PR Newswire August 17, 2016

Seqirus announces shipment of FLUAD™ (Influenza Vaccine, Adjuvanted) in the US for 2016-2017 flu season

PR Newswire August 16, 2016

CSL Behring Announces Immunoglobulin Research Grant Winners

PR Newswire June 23, 2016

AFSTYLA® - CSL Behring's Novel Recombinant Factor VIII Single Chain Therapy for Hemophilia A - Now Available in the U.S.

PR Newswire June 20, 2016

U.S. FDA Approves CSL Behring's AFSTYLA® -- The First and Only Recombinant Factor VIII Single Chain Therapy for Hemophilia A

PR Newswire May 26, 2016